Jazz Bought One Epilepsy Drug. The Rest Just Raised $90M to Go It Alone
Setara Biosciences launches with $90 million to carry Actio's remaining pipeline, led by a TRPV4 inhibitor for a 2,500-patient neuropathy and a much larger overactive bladder market. The structure may become a template for pharma spinouts.